Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 18
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Martin Olin | Chief Executive Officer | 874,04k | N/A | 1969 |
Mr. Rune Skeie | Chief Financial Officer | 232,92k | N/A | 1973 |
Ms. Gayle M. Mills M.B.A | Chief Business Officer | N/A | N/A | 1955 |
Ms. Cristina Oliva M.D. | Chief Medical Officer | 31,18k | N/A | N/A |
Graham Morell | Head of IR | N/A | N/A | N/A |
Dr. Akil Jackson | Medical Director | N/A | N/A | N/A |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
BerGenBio ASAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.